F V Leopardi
Overview
Explore the profile of F V Leopardi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
173
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Samy K, Davis R, Gao Q, Martin B, Song M, Cano J, et al.
Am J Transplant
. 2017 Nov;
18(4):998-1006.
PMID: 29178588
Porcine islet xenografts have the potential to provide an inexhaustible source of islets for β cell replacement. Proof-of-concept has been established in nonhuman primates. However, significant barriers to xenoislet transplantation...
2.
Samy K, Anderson D, Lo D, Mulvihill M, Song M, Farris A, et al.
Am J Transplant
. 2016 Nov;
17(5):1193-1203.
PMID: 27888551
Costimulation blockade (CoB) via belatacept is a lower-morbidity alternative to calcineurin inhibitor (CNI)-based immunosuppression. However, it has higher rates of early acute rejection. These early rejections are mediated in part...
3.
Burghuber C, Kwun J, Page E, Manook M, Gibby A, Leopardi F, et al.
Am J Transplant
. 2015 Dec;
16(6):1726-38.
PMID: 26705099
We have established a model of sensitization in nonhuman primates and tested two immunosuppressive regimens. Animals underwent fully mismatched skin transplantation, and donor-specific antibody (DSA) response was monitored by flow...
4.
Freitas A, Samy K, Farris A, Leopardi F, Song M, Stempora L, et al.
Am J Transplant
. 2015 Jul;
15(8):2240-9.
PMID: 26139552
Vascularized composite allografts (VCAs) are technically feasible. Similar to other organ transplants, VCAs are hampered by the toxicity and incomplete efficacy associated with conventional immunosuppression. Complications attributable to calcineurin inhibitors...
5.
Martin B, Samy K, Lowe M, Thompson P, Cano J, Farris A, et al.
Am J Transplant
. 2015 Feb;
15(5):1241-52.
PMID: 25702898
Islet xenotransplantation is a potential treatment for diabetes without the limitations of tissue availability. Although successful experimentally, early islet loss remains substantial and attributed to an instant blood-mediated inflammatory reaction...
6.
Lowe M, Badell I, Turner A, Thompson P, Leopardi F, Strobert E, et al.
Am J Transplant
. 2013 Jan;
13(2):312-9.
PMID: 23279640
Calcineurin inhibitors (CNI) and steroids are known to promote insulin resistance, and their avoidance after islet transplantation is preferred from a metabolic standpoint. Belatacept, a B7-specific mediator of costimulation blockade...
7.
Badell I, Russell M, Cardona K, Shaffer V, Turner A, Avila J, et al.
Am J Transplant
. 2012 Mar;
12(7):1918-23.
PMID: 22458552
Islet transplantation to treat type 1 diabetes has been limited in part by toxicities of current immunosuppression and recipient humoral sensitization. Blockade of the CD28/CD80/86 and CD40/CD154 pathways has shown...
8.
Badell I, Thompson P, Turner A, Russell M, Avila J, Cano J, et al.
Am J Transplant
. 2011 Sep;
12(1):126-35.
PMID: 21920020
Costimulation blockade of the CD40/CD154 pathway has been effective at preventing allograft rejection in numerous transplantation models. This strategy has largely depended on mAbs directed against CD154, limiting the potential...
9.
Dhanireddy K, Bruno D, Weaver T, Xu H, Zhang X, Leopardi F, et al.
Am J Transplant
. 2008 Nov;
9(1):124-31.
PMID: 18976300
Pretransplant exposure to donor antigen is known to modulate recipient alloimmunity, and frequently results in sensitization. However, donor-specific transfusion (DST) can have a protolerant effect that is dependent on route,...